Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy

Abstract

Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common being Alzheimer’s disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 PSP cases and 3,247 controls (Stage 1) followed up by a second stage where 1,051 cases and 3,560 controls were genotyped for Stage 1 SNPs that yielded P ≤ 10⁻³. We found significant novel signals (P < 5 × 10⁻⁸) associated with PSP risk at STX6, EIF2AK3, and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response, and for a myelin structural component.

PSP is a rare neurodegenerative movement disorder clinically characterized by falls, axial rigidity, vertical supranuclear gaze palsy, bradykinesia, and cognitive decline. Though PSP is rare (prevalence is 3.1–6.5/100,000¹), after Parkinson’s disease (PD), PSP is the second most common cause of degenerative parkinsonism². PSP is a tauopathy with abnormal accumulation of tau protein within neurons as neurofibrillary tangles (NFTs), primarily in the basal ganglia, diencephalon, and brainstem, with neuronal loss in globus pallidus, subthalamic nucleus and substantia nigra. Abnormal tau also accumulates within oligodendroglia and astrocytes³. In Alzheimer’s disease (AD), even though all cases have NFTs, Aβ plaques are closely tied to the primary disease process, and thus AD is a secondary tauopathy. PSP is a primary tauopathy because tau is the major abnormal protein observed. Both environmental insults and inherited factors contribute to the risk of developing tauopathies⁴. Repetitive brain trauma, associated with certain sports, can cause chronic traumatic encephalopathy associated with tau deposits⁵. Viral encephalitis, associated with subsequent parkinsonism, is also associated with tau neuropathology. In PSP, neurotoxins⁴ and low education levels⁶ may also contribute to risk. Genetic risk for PSP is in part determined by variants at a 1 Mb inversion polymorphism that contains a number of genes including MAPT, the gene that encodes tau⁷. The inversion variants are called H1 and H2 “haplotypes”, with H1 conferring risk for PSP⁸. H1 also contributes to risk for corticobasal degeneration^9,10 and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex¹¹, both rare tauopathies. H1 does not contribute to risk for AD. Surprisingly, H1 is also a risk factor for PD¹², a movement disorder with clinical features that overlap those of PSP, yet in PD there are no neuropathologically recognizable tau containing lesions.

We performed a genome wide association (GWA) study of PSP to identify genes that modify risk for this primary tauopathy. We performed a two-stage analysis to maximize efficiency while maintaining power^13,14. For Stage 1 we used only autopsied cases (n = 1,114), thereby essentially eliminating incorrect diagnoses. These were contrasted with 3,287 controls; 96% of cases and 90% of controls were of European ancestry (Table 1, Supplementary Table 1). We assessed association between genotypes at 531,451 single nucleotide polymorphisms (SNPs) and PSP status among subjects of all ancestries (Supplementary Table 2) and those of only European ancestry (Table 2) using an additive model. Results from both ancestry groups were similar. Because our control samples were younger than cases, we compared their allele frequencies at significant and strongly suggestive SNPs to those of older controls (N = 3,816) from three datasets from the NIH repository Database for Genotypes and Phenotypes (Supplementary Table 3). Only SNPs with no significant differences in allele frequencies between old and young controls are presented in Table 2.

Table 1.

Characteristics of the samples^a

Cohort	Total sample analyzed	Gender (male)		Onset Age				Age-at-death				Disease Duration
		Percent	nb	Mean age	Range	SD (±)	n	Mean age	range	SD (±)	n	Mean duration (years)	range	SD (±)	n
PSP stage 1c	1,114	55	599	68	(41–93)	8.2	827	75	45–99	8.0	1,070	7.4	1–21	3.2	827
PSP stage 1 European Ancestry	1,069	55	570	68	(41–93)	8.3	794	75	45–99	8.0	1,025	7.4	1–21	3.1	794
PSP stage 2d	1,051	53	530	65	(40–91)	7.3	913	75	57–94	7.4	118	8.0	<1–18	3.3	42

^aControls were young normal subjects recruited from the Children's Hospital of Philadelphia Health Care Network (See Online Methods for details). These were 3,287 controls for Stage 1 and 3,560 for Stage 2;

^bn, number of samples with available data. Values of n for each type of analysis do not add up to the total samples used because of missing values;

^cStage 1 consisted of autopsy-confirmed cases.

^dThe stage 2 dataset included 130 cases with autopsies. All stage 2 samples (cases and controls) were independent of stage 1 samples.

Table 2.

Results from Stage 1, Stage 2, and joint analysis among subjects of European Ancestry: SNPs Significant at P < 5 × 10⁻⁸ in the joint analysis

Chr band	SNP Location (bp)	Gene or nearby gene	Stage 1				Stage 2				Joint P
			MAFa Case	MAF Contb	ORc/CI	P1	MAF Case	MAF Cont	OR / CI	P2	OR/CI	PJ
1q25.3	rs1411478 179,229,155	STX6	0.50	0.42	0.73 0.65 – 0.81	1.8 × 10−9	0.46	0.43	0.85 0.77 – 0.94	1.5 × 10−3	0.79 0.74 – 0.85	2.3 × 10−10
2p11.2	rs7571971 88,676,716	EIF2AK3	0.31	0.26	0.75 0.66 – 0.84	7.4 × 10−7	0.31	0.25	0.75 0.67 – 0.83	8.7 × 10−8	0.75 0.69 – 0.81	3.2 × 10−13
3p22.1	rs1768208 39,498,257	MOBP	0.36	0.29	0.70 0.63 – 0.79	10 × 10−10	0.35	0.29	0.74 0.67 – 0.82	1.3 × 10−8	0.72 0.67 – 0.78	1.0 × 10−16
17q21.31	rs8070723 41,436,651	MAPT	0.05	0.23	5.50 4.40 – 6.86	2.1 × 10−51	0.06	0.23	4.74 3.92 – 5.74	4.8 × 10−67	5.46 4.72 – 6.31	1.5 × 10−116
	rs242557 41,375,823	MAPT	0.53	0.35	0.48 0.43 – 0.53	2.2 × 10−37	0.50	0.36	0.54 0.48 – 0.59	5.0 × 10−35	0.51 0.47 – 0.55	4.2 × 10−70
	crs242557/ rs8070723	MAPT	---	---	0.66 0.58 – 0.74	1.3 × 10−11	---	---	0.74 0.67 – 0.83	6.3 × 10−8	0.70 0.65 – 0.76	9.5 × 10−18

^aMAF, minor allele frequency;

^bOR based on major allele,

^crs242557 controlling for rs8070723;

Abbreviations and gene symbols: P₁, stage 1 P value; P₂, stage 2 P value; P_J, joint P value; STX6, syntaxin 6; EIF2AK3, eukaryotic translation initiation factor 2-α kinase 3; MOBP, myelin-associated oligodendrocyte basic protein; MAPT, microtubule associated protein tau; a summary of the function of each gene listed is in Supplementary Table 9. Associations were determined using an additive genetic model. Exploratory analyses (results not shown) of PSP using dominant and recessive models did not produce new loci although some of the associations in 17q21.31 were also consistent with these non-additive models. These less parsimonious models did not fit the data significantly better than the additive model. By evaluating 5000 SNPs with the smallest P-values in more complicated models involving main effects and interactions³⁸, no noteworthy gene-gene interactions were uncovered. There were additional SNPs in the regions for the above loci that were significant or strongly suggestive for association; however, they were no longer significant after controlling the most significant SNP in the region (Supplementary Table 5). All loci significant in the joint analyses remained so after controlling for the MAPT inversion (Supplementary Table 10).

Stage 1 P-values (P₁) for SNPs in three regions crossed the significance threshold of P < 5 × 10⁻⁸ (Table 2, Fig. 1). At 1q25.3, a SNP in STX6 crossed this threshold (P₁ = 1.8 × 10⁻⁹). Another SNP at 3p22.1 in MOBP crosses this threshold (P₁ = 1.0 × 10⁻⁹). The third region was 17q21.31, in which 58 SNPs had P₁ < 5 × 10⁻⁸ (Table 2, Fig. 2a). This focus of association is the approximately 1 Mb H1/H2 inversion polymorphism containing MAPT¹⁵.

Figure 1.

(a) Association results for 1q25.3 STX6. (b) Association results for 2p11.2 EIF2AK3. (c) Association results for 3p22.1 MOBP regions. –log10 P values are shown for Stages 1 and 2 and the joint analyses. Recombination rate, calculated from the linkage disequilibrium (LD) structure of the region, is derived from Hapmap3 data. LD, encoded by intensity of the colors, is the pairwise LD of the most highly associated SNP at Stage 1 with each of the SNPs in the region. Transcript positions are shown below each graph.

Figure 2.

(a) Association results for the 17q21.31 H1/H2 inversion polymorphism (40,974,015 – 41,926,692 Kb) and flanking segments. (b) Association results for 17q21.31 controlling for H1/H2. Results are shown for Stages 1 and 2 and the joint analyses. Recombination rate, calculated from the linkage disequilibrium (LD) structure of the region, is derived from Hapmap3 data. LD, encoded by intensity of the colors, is the pairwise LD of the most highly associated SNP at Stage 1 with each of the SNPs in the region.

SNPs for Stage 2 were selected from the original set if they yielded a P₁ < 10⁻³. We assessed 4,099 SNPs for association in 1,051 cases, mostly living subjects clinically diagnosed with PSP (Supplementary Table 4) and 3,560 control subjects, all of European ancestry. We also included 197 ancestry informative markers¹⁶ to evaluate population substructure. Clinically diagnosed PSP¹⁷ is reasonably concordant with autopsy results¹⁸. We estimated the diagnostic misclassification rate as 12%, which has only a small impact on power (Online Methods).

All three loci associated in Stage 1, were replicated by joint analysis (Table 2, Figs. 1 and 2). Joint analysis revealed two new loci with joint P-values (P_J) below the genome-wide significant threshold. One was at 2p11.2, within EIF2AK3 (P_J = 3.2 × 10⁻¹³). Another, rs12203592 (P_J = 6.2 × 10⁻¹⁵), at 6p25.3, highlighted IRF4, with a neighboring SNP in EXOC2, rs2493013 (P_J = 6.0 × 10⁻⁷); rs2493013 was significant after controlling for rs12203592 at P < 1 × 10⁻³ (Supplementary Table 5). However, allele frequencies for rs12203592 and rs2493013 in older controls were significantly different from those of our controls (Supplementary Table 3). Curiously, the older control data sets were all significantly different from each other. While rs12203592 alleles frequencies vary widely across Europe¹⁹, we could not ascribe these fluctuations amongst controls to either ancestry or genotyping artifacts. In the joint analysis, 3 other loci reached suggestive association (an intergenic region at 1q41, P_J = 2.8 × 10⁻⁷; BMS1, P_J = 4.9 × 10⁻⁷; SLCO1A2, P_J = 1.9 × 10⁻⁷; Supplementary Table 6 and Figure 5).

In the MAPT region, most of the PSP-associated SNPs mapped directly or closely onto H1/H2, producing very small P-values (e.g., for rs8070723, P₁ = 2.1 × 10⁻⁵¹, P_J = 1.5 × 10⁻¹¹⁶). H1 confers risk and 95% of PSP subject chromosomes are H1 compared to 77.5% of control chromosomes. In the Stage 1 autopsy cases, the odds ratio (OR) is 5.5 [confidence interval (C.I.) 4.4 – 6.86, Table 2], which is stronger than the OR for the APOE ε3/ε4 genotype as a risk locus for AD²⁰. The OR for the Stage 2 PSP samples was comparable to the Stage 1 OR, evidence that the clinically and autopsy-diagnosed cohorts are similar in composition.

If all of the risk from 17q21.31 were associated with H1/H2, controlling for H1/H2 (using rs8070723 as a proxy) should be sufficient to make association at all other loci in this region non-significant. That is not the case; instead certain SNPs remained associated, with the maximum falling in MAPT (rs242557) (Table 2, Figure 2, Supplementary Table 5). No other 17q21.31 SNPs showed association after controlling for rs8070723 and rs242557 genotypes. SNP rs242557 was previously identified as a key regulatory polymorphism influencing MAPT expression²¹. Note that rs242557 accounts for only part of the total risk associated with H1/H2 (Table 2).

The SNPs used to detect a GWA signal are not necessarily the risk-causing variants. For STX6 and EIF2AK3, there are non-synonymous SNPs in close proximity to and highly correlated with the top GWA SNPs (Supplementary Table 7) making these coding changes candidates for the pathogenic change. To evaluate the possibility that some risk-variants regulate gene expression, we analyzed the correlations between gene expression levels from two brain regions of 387 normal subjects and SNP genotypes for the regions listed in Table 2. Two regions showed strong genotype-expression associations (Fig. 3). SNPs falling in or near MOBP have some effect on MOBP expression, but are more strongly correlated with SLC25A38 expression, which is 70 kb from MOBP (Fig. 3a). This effect on SLC25A38 is seen in cerebellum but is weaker in the frontal cortex.

Figure 3.

(a) Association results for the relationship between SNP genotypes and mRNA transcripts from the cerebellum and frontal cortex for the SLC25S38/MOBP region. (b) Association results for the relationship between SNP genotypes and mRNA transcripts from the cerebellum and frontal cortex for the H1/H2 inversion polymorphism region. (c) Association results for the relationship between SNP genotypes and mRNA transcripts from the cerebellum and frontal cortex for the H1/H2 inversion polymorphism region controlling for H1/H2. The color of the circle corresponds to the color assigned each gene and each SNP is tested against multiple cis transcripts. The data presented here are independent samples from those used previously by Simon-Sanchez et al.¹².

The second region showing a strong genotype-expression correlation is the MAPT inversion region. SNP alleles across the entire H1/H2 inversion and flanking regions show strong correlation with not only MAPT expression (p = 8.71 × 10⁻²⁸ for multiple SNPs), but also with ARL17A (P = 9.2 × 10⁻²²), PLEKHM1 (P = 1.0 × 10⁻⁹), and LRRC37A4 (P = 2.2 × 10⁻³⁵)¹². Note that while MAPT expression is correlated with SNPs across the entire inversion region, the SNPs influencing ARL17A are associated with a subset of regional SNPs and these are not identical to the SNPs affecting MAPT expression. Expression of CRHR1 and KIAA1267, genes that are in the inversion region and that flank MAPT, is not correlated with H1/H2 SNPs.

To distinguish between the effects on gene expression of the inversion versus other independent effects, we controlled for H1/H2 as was done for association with PSP (Table 2). After controlling for H1/H2, all significant genotype-expression correlation for MAPT and LRRC37A4 disappears (Fig. 3c) showing that either the orientation of this region or a polymorphism that maps onto H1/H2, determines MAPT expression. In contrast, controlling for H1/H2 has no effect on genotype-expression correlations for ARL17A. Potential eSNPs for ARL17A include rs242557 (Table 2), which is highly associated with PSP but more modestly correlated with ARL17A expression, and rs8079215, which is highly correlated with ARL17A expression but not as strongly with risk for PSP. Statistical modeling of these data produce the following conclusions: haplotypes involving H1 and rs242557 alleles predict a highly significant portion of the variability of ARL17A expression; however, essentially all of that variance can be explained by alleles at rs8079215, which are correlated with H1/H2 and rs242557 alleles; and that alleles at rs8079215 cannot predict risk for PSP independent of H1/H2 status even though they are excellent predictors of ARL17A expression. In sum, risk for PSP does not rise and fall with ARL17A expression. The global MAPT brain region expression analyzed here does not explain how rs242557 alleles confer risk to PSP. Yet this SNP or a correlated polymorphism is assumed to have a regulatory effect because there are no coding variants in MAPT brain isoforms that are candidate pathogenic variants. One possible explanation is that rs242557 alleles could affect alternative splicing without altering total MAPT expression levels^22,23.

Because AD and PSP are tauoptahies, and because H1 is a shared risk factor for PSP and PD, we determined whether any confirmed AD^24–28 or PD²⁹ loci also produced suggestive evidence for PSP association (Supplementary Table 8). Besides the overlap between PD and PSP at MAPT, the single noteworthy result was from rs2075650 in TOMM40 that yielded P_J = 1.28 × 10⁻⁵ for association with PSP. TOMM40 is adjacent to APOE and rs2075650 tags the AD risk allele, e4, in APOE. The effect in PSP is opposite that seen in AD: e4 frequency is elevated in AD and diminished in PSP (for rs2075650, the estimated MAF in cases is 0.11 versus 0.15 in both our young and older controls; r² between rs2075650 and e4 is 0.33).

Our work suggests a number of intriguing insights into PSP. One comes from EIF2AK3, a gene that encodes PERK, a component of the endoplasmic reticulum (ER) unfolded protein response (UPR). When excess unfolded proteins accumulate in the ER, PERK is activated and protein synthesis is inhibited allowing the ER to clear mis-folded proteins and return to homeostasis. The UPR is active in PSP³⁰, AD³¹, and PD³². In PSP, activated PERK is in neurons, oligodendrocytes, and astrocytes³⁰. In AD, activated UPR components are found in pre-tangle neurons in a number of brain regions³¹. In PD, UPR activation occurs in neuromelanin containing dopaminergic neurons in the substantia nigra³². How the UPR contributes to PSP pathogenesis is unclear because the primary mis-folded protein in PSP, tau, is not a secreted protein and thus is not expected to traffic through the ER.

The PSP susceptibility gene STX6 encodes syntaxin 6 (Stx6), a SNARE class protein. SNARE proteins are part of the cellular machinery that catalyzes the fusion of vesicles with membranes³³. Stx6 is localized to the trans-Golgi network and endosomal structures³⁴. Since our work implicates ER-stress in PSP pathogenesis, genetic variation at STX6 could influence movement of mis-folded proteins from the ER to lysosomes via the endosomal system.

MOBP (P_J = 1 × 10⁻¹⁶), like the myelin basic protein gene (MBP), encodes a protein (MOBP) that is produced by oligodendrocytes and is present in the major dense line of CNS myelin. MOBP is highly expressed in the white matter of the medulla, pons, cerebellum, and midbrain³⁵, regions affected in PSP. Our findings suggest that myelin dysfunction or oligodendrocyte mis-function contributes to PSP pathogenesis.

Our work generates a testable translational hypothesis based on the results for EIK2AK3. Our work suggests that perturbation of the UPR can influence PSP risk, and that the UPR is not just a downstream consequence of neurodegeneration. Thus pharmacologic modulation of the UPR is a potential therapeutic strategy for PSP^36,37.

PSP Genetics Study Group coauthors

Roger L. Albin^31,32, Elena Alonso^33,34, Angelo Antonini^35,36, Manuela Apfelbacher³⁷, Steven E. Arnold³⁸, Jesus Avila³⁹, Thomas G. Beach⁴⁰, Sherry Beecher⁴¹, Daniela Berg⁴², Thomas D. Bird⁴³, Nenad Bogdanovic⁴⁴, Agnita J.W. Boon⁴⁵, Yvette Bordelon⁴⁶, Alexis Brice^47,48,49, Herbert Budka⁵⁰, Margherita Canesi³⁵, Wang Zheng Chiu⁴⁵, Roberto Cilia³⁵, Carlo Colosimo⁵¹, Peter P. De Deyn⁵², Justo García de Yebenes⁵³, Laura Donker Kaat⁴⁵, Ranjan Duara⁵⁴, Alexandra Durr^47,48,49, Sebastiaan Engelborghs⁵², Giovanni Fabbrini⁵¹, NiCole A. Finch⁵⁵, Robyn Flook⁵⁶, Matthew P. Frosch⁵⁷, Carles Gaig⁵⁸, Douglas R. Galasko⁵⁹, Thomas Gasser⁴², Marla Gearing⁶⁰, Evan T. Geller⁴¹, Bernardino Ghetti⁶¹, Neill R. Graff-Radford⁶², Murray Grossman⁶³, Deborah A. Hall⁶⁴, Lili-Naz Hazrati⁶⁵, Matthias Höllerhage⁶⁶, Joseph Jankovic⁶⁷, Jorge L. Juncos⁶⁸, Anna Karydas⁶⁹, Hans A. Kretzschmar⁷⁰, Isabelle Leber^47,48,49, Virginia M. Lee⁴¹, Andrew P. Lieberman⁷¹, Kelly E. Lyons⁷², Claudio Mariani³⁵, Eliezer Masliah^59,73, Luke A. Massey⁷⁴, Catriona A. McLean⁷⁵, Nicoletta Meucci³⁵, Bruce L. Miller⁶⁹, Brit Mollenhauer^76,77, Jens C. Möller⁶⁶, Huw R. Morris⁷⁸, Chris Morris⁷⁹, Sean S. O’Sullivan⁷⁴, Wolfgang H. Oertel⁶⁶, Donatella Ottaviani⁵¹, Alessandro Padovani⁸⁰, Rajesh Pahwa⁷², Gianni Pezzoli³⁵, Stuart Pickering-Brown⁸¹, Werner Poewe⁸², Alberto Rabano⁸³, Alex Rajput⁸⁴, Stephen G Reich⁸⁵, Gesine Respondek⁶⁶, Sigrun Roeber⁷⁰, Jonathan D. Rohrer⁸⁶, Owen A. Ross⁵⁵, Martin N. Rossor⁸⁶, Giorgio Sacilotto³⁵, William W. Seeley⁶⁹, Klaus Seppi⁸², Laura Silveira-Moriyama⁷⁴, Salvatore Spina⁶¹, Karin Srulijes⁴², Peter St. George-Hyslop^65,87, Maria Stamelou⁶⁶, David G. Standaert⁸⁸, Silvana Tesei³⁵, Wallace W. Tourtellotte⁸⁹, Claudia Trenkwalder⁷⁷, Claire Troakes⁹⁰, John Q. Trojanowski⁴¹, Juan C. Troncoso⁹¹, Vivianna M. Van Deerlin⁴¹, Jean Paul G. Vonsattel⁹², Gregor K. Wenning⁸², Charles L. White⁹³, Pia Winter⁹⁴, Chris Zarow⁹⁵, Anna L. Zecchinelli³⁵

PSP Genetics Study Group coauthor affiliations ³¹Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. ³²Geriatrics Research, Education, and Clinical Center, VA Ann Arbor Health System, Ann Arbor, Michigan, USA. ³³Neurogenetics laboratory, Division of Neurosciences, University of Navarra Center for Applied Medical Research, Pamplona, Spain. ³⁴Neurogenetics laboratory, Division of Neurosciences, University of Navarra Center for Applied Medical Research, Pamplona, Spain. ³⁵Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy. ³⁶Department for Parkinson's Disease, IRCCS San Camillo, Venice, Italy. ³⁷Institute of Legal Medicine, University of Würzburg, Würzburg, Germany. ³⁸Department of Psychiatry, Center for Neurobiology and Behavior, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. ³⁹Centro de Biologia Molecular Severo Ochoa (CSIC-UAM), Campus Cantoblanco, Universidad Autonoma de Madrid, Madrid, Spain. ⁴⁰Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA. ⁴¹Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. ⁴²Center of Neurology, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative diseases (DZNE), Tübingen, Germany. ⁴³Departments of Medicine, Neurology, and Medical Genetics, University of Washington, Seattle, Washington, USA. ⁴⁴Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Hudding University Hospital, Stockholm, Sweden. ⁴⁵Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁴⁶Department of Neurology, University of California Los Angeles, Los Angeles, California, USA. ⁴⁷Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, Université Pierre et Marie Curie, Paris, France. ⁴⁸Institut National de la Santé et de la Recherche Médicale, Paris, France. ⁴⁹Centre National de la Recherche Scientifique, Paris, France. ⁵⁰Institute of Neurology, Medical University Vienna, Vienna, Austria. ⁵¹Dipartimento di Scienze Neurologiche e Psichiatriche, Sapienza Università di Roma, Rome, Italy. ⁵²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. ⁵³Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain. ⁵⁴Wien Center for Alzheimer's Disease and Memory Disorders, Mt Sinai Medical Center, Miami Beach, Florida, USA. ⁵⁵Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. ⁵⁶Centre for Neuroscience, Flinders University and Australian Brain Bank Network, Victoria, Australia. ⁵⁷C.S. Kubik Laboratory for Neuropathology and Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁵⁸Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. ⁵⁹Department of Neurosciences, University of California San Diego, La Jolla, California, USA. ⁶⁰Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. ⁶¹Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. ⁶²Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. ⁶³Department of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA. ⁶⁴Department of Neurological Sciences, Rush University, Chicago, IL, USA. ⁶⁵Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada. ⁶⁶Department of Neurology, Philipps University, Marburg, Germany. ⁶⁷Department of Neurology, Baylor College of Medicine, Houston, TX, USA. ⁶⁸Depratment of Neurology, Emory University, Atlanta, GA, USA. ⁶⁹Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA. ⁷⁰Institut für Neuropathologie, Ludwig-Maximilians-Universität and Brain Net Germany, Munich, Germany. ⁷¹Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. ⁷²Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA. ⁷³Department of Pathology, University of California San Diego, La Jolla, CA, USA. ⁷⁴Reta Lila Weston Institute, UCL Institute of Neurology, University College London, London, UK. ⁷⁵Victorian Brain Bank Network, Mental Health Research Institute, Victoria, Australia. ⁷⁶Department of Neurology, Georg-August University, Goettingen, Germany. ⁷⁷Paracelsus-Elena-Klinik, University of Goettingen, Kassel, Germany. ⁷⁸MRC Centre for Neuropsychiatric Genetics and Department of Neurology, School of Medicine, Cardiff University, Cardiff, UK. ⁷⁹Newcastle Brain Tissue Resource, Newcastle University, Institute for Ageing and Health, Newcastle upon Tyne, UK. ⁸⁰Department of Medical and Surgical Sciences, Institute of Neurology, University of Brescia, Brescia, Italy. ⁸¹Neurodegeneration and Mental Health Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester, UK. ⁸²Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. ⁸³Department of Neuropathology and Tissue Bank Fundación CIEN, Instituto de Salud Carlos III, Madrid, Spain. ⁸⁴Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatchewan, Canada. ⁸⁵Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA. ⁸⁶Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK. ⁸⁷Cambridge Institute for Medical Research and Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. ⁸⁸Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA. ⁸⁹Human Brain and Spinal Fluid Resource Center, Veterans Affairs West Los Angeles Healthcare Center, Los Angeles, CA, USA. ⁹⁰Department of Clinical Neuroscience, MRC Centre for Neurodegeneration Research, King's College London, London, UK. ⁹¹Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁹²Department of Pathology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York City, NY, USA. ⁹³Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. ⁹⁴Institute of Human Genetics, Justus-Liebig University, Giessen, Germany. ⁹⁵Rancho Los Amigos National Rehabilitation Center, University of Southern California, Downey, CA, USA.